Skip to navigation Skip to content

Systemic light chain amyloidosis (AL) Program in Pharmaceutical Benefits Scheme (PBS) 012-22121931

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised daratumumab for patients with systemic light chain amyloidosis.

AL and listing dates

Systemic light chain amyloidosis is a rare disease that occurs when a protein called amyloid builds up in organs.

Listing date:

  • daratumumab - 1 January 2023

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS authority approvals line.

The Resources page contains:

  • application forms
  • contact details
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs